206640.KQ

Boditech Med Inc. [206640.KQ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

206640.KQ Stock Summary

Earnings have grown 13.67% per last year.

The Moving Average Convergence Divergence (MACD) for 206640.KQ recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

206640.KQ has less than 1 year of cash runway

In the News

206640.KQ Financial details

Company Rating

Strong Buy

Market Cap

319.65B

Income

25.95B

Revenue

134.22B

Book val./share

8475.58

Cash/share

3468.46

Dividend

Dividend %

Employees

457

Optionable

Shortable

Yes

Earnings

13 Feb 2023

P/E

16.01

Forward P/E

PEG

17.09

P/S

3.23

P/B

2.28

P/C

4.28

P/FCF

15.67

Quick Ratio

4.19

Current Ratio

6.55

Debt / Equity

0.05

LT Debt / Equity

0.01

EPS (TTM)

1.18K

EPS next Y

EPS next Q

EPS this Y

9.37%

EPS next Y

EPS next 5Y

EPS last 5Y

18.44%

Revenue last 5Y

13.02%

Revenue Q/Q

0.19%

EPS Q/Q

-47.18%

SMA20

-1.52%

SMA50

-17.03%

SMA100

-16.87%

Inst Own

Inst Trans

ROA

12%

ROE

15%

ROC

0.15%

Gross Margin

60%

Oper. Margin

23%

Profit Margin

20%

Payout

13%

Shs Outstand

Shs Float

Target Price

52W Range

11230.0-22150.0

52W High

-32.96%

52W Low

+32.24%

RSI

Rel Volume

0.63

Avg Volume

176.95K

Volume

110.79K

Perf Week

5.69%

Perf Month

-3.19%

Perf Quarter

-13.11%

Perf Half Y

-22.41%

Beta

-0.53

Volatility

509.77%, 484.72%

Prev Close

0.88%

Price

14850

Change

-1.26%

206640.KQ Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.17K	6.27K	6.89K	5.28K	6.11K
Net income per share	506.66	1.98K	1.94K	1.08K	1.18K
Operating cash flow per share	749.87	1.94K	2.18K	1.03K	1.56K
Free cash flow per share	529.38	1.75K	1.38K	275.59	1.31K
Cash per share	1.08K	2.57K	2.99K	2.7K	3.47K
Book value per share	3.2K	5.21K	6.6K	7.31K	8.48K
Tangible book value per share	3.07K	5.29K	6.84K	7.62K	8.97K
Share holders equity per share	3.2K	5.21K	6.6K	7.31K	8.48K
Interest debt per share	719.52	510.16	270.57	367.97	471.95
Market cap	221.89B	545B	384.77B	224.76B	445.95B
Enterprise value	214.05B	532.88B	352.82B	207.39B	414.03B
P/E ratio	19.05	11.98	8.67	9.31	17.19
Price to sales ratio	3.05	3.78	2.44	1.9	3.32
POCF ratio	12.87	12.21	7.71	9.74	13
PFCF ratio	18.23	13.51	12.21	36.47	15.55
P/B Ratio	3.02	4.55	2.55	1.37	2.4
PTB ratio	3.02	4.55	2.55	1.37	2.4
EV to sales	2.94	3.7	2.24	1.76	3.08
Enterprise value over EBITDA	12.29	7.51	6.22	6.74	11.83
EV to operating cash flow	12.41	11.94	7.07	8.99	12.07
EV to free cash flow	17.59	13.21	11.19	33.65	14.44
Earnings yield	0.05	0.08	0.12	0.11	0.06
Free cash flow yield	0.05	0.07	0.08	0.03	0.06
Debt to equity	0.2	0.09	0.04	0.05	0.05
Debt to assets	0.15	0.07	0.03	0.04	0.04
Net debt to EBITDA	-0.45	-0.17	-0.56	-0.56	-0.91
Current ratio	3.36	3.65	4.83	7.28	5.09
Interest coverage	7.12	140.54	257.69	114.34	76.42
Income quality	1.48	0.98	1.13	0.96	1.32
Dividend Yield	0.01	0	0.01	0.02	0.01
Payout ratio	0.1	0.03	0.1	0.18	0.13
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.15	0.08	0.1	0.14	0.11
Intangibles to total assets	0.07	0.03	0.02	0.02	0
Capex to operating cash flow	-0.29	-0.1	-0.37	-0.73	-0.16
Capex to revenue	-0.07	-0.03	-0.12	-0.14	-0.04
Capex to depreciation	-1	-0.8	-3.05	-2.26	-0.68
Stock based compensation to revenue	0	0	0	0	0
Graham number	6.04K	15.23K	16.96K	13.33K	15.01K
ROIC	0.13	0.4	0.27	0.13	0.12
Return on tangible assets	0.12	0.29	0.24	0.13	0.11
Graham Net	895.24	2.67K	3.25K	3.28K	3.8K
Working capital	40.56B	88.14B	103.97B	101.19B	111.41B
Tangible asset value	70.52B	121.67B	156.76B	170.38B	197.1B
Net current asset value	33.56B	84.07B	100.07B	96.48B	108.19B
Invested capital	0.2	0.09	0.04	0.05	0.05
Average receivables	15.36B	26.7B	31.85B	25.68B	26.74B
Average payables	1.46B	3.73B	6.28B	4B	3.41B
Average inventory	14.95B	19.38B	28.74B	32.13B	31.23B
Days sales outstanding	83.88	92.86	62.56	75.22	79.25
Days payables outstanding	14.21	46.32	37.98	11.38	33.24
Days of inventory on hand	158.32	181.35	197.75	222.21	200.56
Receivables turnover	4.35	3.93	5.83	4.85	4.61
Payables turnover	25.68	7.88	9.61	32.07	10.98
Inventory turnover	2.31	2.01	1.85	1.64	1.82
ROE	0.16	0.38	0.29	0.15	0.14
Capex per share	-220.5	-186.6	-803.89	-755.91	-256.29

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.31K	1.34K	1.59K	1.59K	1.59K
Net income per share	218.69	252.69	285.81	420.49	222.12
Operating cash flow per share	355.84	275.4	333.71	416.56	535.66
Free cash flow per share	289.51	229.56	286.8	347.45	441.25
Cash per share	2.75K	3.03K	2.87K	3.2K	3.47K
Book value per share	7.45K	7.57K	7.84K	8.27K	8.48K
Tangible book value per share	7.76K	7.89K	8.17K	8.58K	8.97K
Share holders equity per share	7.45K	7.57K	7.84K	8.27K	8.48K
Interest debt per share	369	381.18	246.08	291.05	460.51
Market cap	220.78B	233.3B	283.16B	405.31B	445.97B
Enterprise value	203.41B	207.47B	247.48B	378.42B	414.04B
P/E ratio	11.49	10.51	11.28	10.97	22.85
Price to sales ratio	7.65	7.91	8.1	11.63	12.77
POCF ratio	28.24	38.56	38.63	44.29	37.9
PFCF ratio	34.71	46.26	44.94	53.1	46.01
P/B Ratio	1.35	1.4	1.64	2.23	2.4
PTB ratio	1.35	1.4	1.64	2.23	2.4
EV to sales	7.05	7.04	7.08	10.85	11.85
Enterprise value over EBITDA	22.53	30.8	25.81	36.3	50.14
EV to operating cash flow	26.02	34.29	33.76	41.35	35.18
EV to free cash flow	31.98	41.14	39.28	49.58	42.71
Earnings yield	0.02	0.02	0.02	0.02	0.01
Free cash flow yield	0.03	0.02	0.02	0.02	0.02
Debt to equity	0.05	0.05	0.03	0.03	0.05
Debt to assets	0.04	0.04	0.03	0.03	0.04
Net debt to EBITDA	-1.92	-3.83	-3.72	-2.58	-3.87
Current ratio	7.28	5.91	7.33	6.55	5.09
Interest coverage	86.12	39.63	116.46	126.38	61.09
Income quality	1.63	1.09	1.17	0.99	2.41
Dividend Yield	0	0	0.01	0	0
Payout ratio	0	0	0.52	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.14	0.13	0.1	0.1	0.12
Intangibles to total assets	0.02	0.02	0.02	0.02	0
Capex to operating cash flow	-0.19	-0.17	-0.14	-0.17	-0.18
Capex to revenue	-0.05	-0.03	-0.03	-0.04	-0.06
Capex to depreciation	-0.71	-0.5	-0.5	-0.76	-0.95
Stock based compensation to revenue	0	0	0	0	0
Graham number	6.05K	6.56K	7.1K	8.84K	6.51K
ROIC	0.05	0.02	0.03	0.04	0.03
Return on tangible assets	0.03	0.03	0.03	0.04	0.02
Graham Net	3.34K	3.48K	3.61K	3.86K	3.79K
Working capital	101.19B	104.75B	108.22B	114.96B	111.41B
Tangible asset value	170.38B	173.31B	179.46B	188.41B	197.1B
Net current asset value	96.48B	100.12B	103.64B	110.6B	108.19B
Invested capital	0.05	0.05	0.03	0.03	0.05
Average receivables	23.93B	25.9B	29.13B	31.59B	30.76B
Average payables	1.68B	1.9B	2.88B	4.19B	5.03B
Average inventory	32.67B	30.68B	30.06B	30.02B	31.02B
Days sales outstanding	75.88	83.85	79.28	83.6	75.09
Days payables outstanding	12.43	15.38	21.38	28.81	32.4
Days of inventory on hand	242.65	212.11	178.01	182.03	195.46
Receivables turnover	1.19	1.07	1.14	1.08	1.2
Payables turnover	7.24	5.85	4.21	3.12	2.78
Inventory turnover	0.37	0.42	0.51	0.49	0.46
ROE	0.03	0.03	0.04	0.05	0.03
Capex per share	-66.34	-45.84	-46.92	-69.12	-94.41

206640.KQ Frequently Asked Questions

What is Boditech Med Inc. stock symbol ?

Boditech Med Inc. is a KR stock and trading under the symbol 206640.KQ

What is Boditech Med Inc. stock quote today ?

Boditech Med Inc. stock price is $14850 today.

Is Boditech Med Inc. stock public?

Yes, Boditech Med Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 176.95K
Market Capitalization 319.65B
Employee 457
CEO Ui-Yeol Choe
Headquarters Chuncheon-si,KR
IPO Date 2015-09-01
Website http://www.boditech.co.kr

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other samples to measure quantitatively or semi-quantitatively the concentration of targeted analytes; ichroma-50, an automatic immunoassay analyzer that measures the concentration of targeted analytes in body fluids, such as blood, urine, and other samples; and ichroma M2, a portable analyzer intended to be used with in vitro diagnostic immunofluorescent assay kits for screening, monitoring and/or examining routine physics in centralized laboratories of hospitals or physician's clinics. The company also provides Ichroma TRIAS Reader, an in vitro diagnostic device that measures the concentration of targeted analyte from various samples, such as blood, nasal swabs, and nasopharyngeal swabs; Hemochroma PLUS, an in vitro diagnostic device to quantitative test total hemoglobin concentration in the blood; i-chamber, an auxiliary device for the ichroma systems; and HandyRay, a laser device for the capillary blood sampling without a needle. Its solutions cover areas, such as cardiac, cancer, diabetes, hormone, infection, infectious disease, gastrointestinal, rheumatoid arthritis, and others. The company offers its products through a network of approximately 100 sales agencies worldwide. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon, South Korea.